Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vertex Pharmaceuticals (NQ: VRTX ) 473.82 -1.13 (-0.24%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Vertex Pharmaceuticals < Previous 1 2 3 4 5 6 Next > Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions June 21, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress June 14, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA® June 07, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex to Participate in Upcoming June Investor Conferences May 22, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Jennifer Schneider Elected to Vertex Board of Directors May 15, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Will the Biotech Sector Shift From Lagger to Leader? May 10, 2024 The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs. Via MarketBeat Topics ETFs Vertex Reports First Quarter 2024 Financial Results May 06, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain April 18, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Enters Into Agreement to Acquire Alpine Immune Sciences April 10, 2024 From Alpine Immune Sciences, Inc. Via Business Wire Vertex to Announce First Quarter 2024 Financial Results on May 6 April 09, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Biotech Sector Nears Breakout: Will it Outperform in Q2? April 03, 2024 The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains Via MarketBeat Topics ETFs Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease April 01, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease” March 25, 2024 Via AB Newswire Exposures Product Safety Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) March 21, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Geron Stock Doubles After Imetelstat Receives FDA Panel Approval March 20, 2024 Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel Via MarketBeat Exposures Product Safety bluebird bio: How to play LEAPS options for growth and income February 27, 2024 Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT Via MarketBeat Exposures Product Safety Is CRISPR Therapeutics the NVIDIA of gene editing? February 26, 2024 CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv Via MarketBeat Topics Artificial Intelligence Exposures Artificial Intelligence Product Safety Vertex to Participate in Upcoming Investor Conferences February 20, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Gene therapy: Why does it cost millions for a single treatment? February 15, 2024 Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. Via MarketBeat Exposures Product Safety European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia February 13, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Reports Fourth Quarter and Full Year 2023 Financial Results February 05, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis February 05, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain January 30, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire 2 gene editing stocks to keep on your 2024 watchlist January 23, 2024 Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Via MarketBeat Exposures Product Safety Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5 January 17, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia January 16, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia January 09, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire 2 low-priced gene therapy stocks to speculate on January 08, 2024 Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe Via MarketBeat Exposures Product Safety Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings January 07, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Will the Biotech sector sustain its momentum in 2024? January 04, 2024 The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%. Via MarketBeat Topics ETFs < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
